Фармакоэкономические аспекты гипотензивной терапии у лиц старше 75 лет

Objective. To carry out a pharmacoeconomic analysis of the antihypertensive therapy in elderly patients of high cardiovascular risk by the means of the method assessing «expenses benefits», cost minimization, the increment of cost efficiency. Results. The cost of the daily efficient dose of the original (Renitec, MSD) and generic Enalapril (Hemofarm) was 6,54 and 7,25 rubles, respectively. Minimal coefficient «expenses benefits» was defined in the group of patients receiving two drug combination therapy including original Enalapril (Renitec, MSD) compared to combination of three drugs including generic Enalapril (Hemofarm) while the antihypertensive effect was comparable. The cost efficiency increment (CER incr) was 169,12 rubles regarding original Enalapril (Renitec, MSD) benefit.